The prestigious award recognises Professor Tate's significant contributions to the development and commercialisation of N-myristoyltransferase (NMT) inhibitors. This work has established a new class of antibody–drug conjugate (ADC) payloads, stemming from the group's research into protein lipidation and its role in cancer.
This innovative approach, which involves delivering NMT inhibitors to tumour cells via antibodies, offers a distinct mechanism of action within the field of ADC development. The research led to the founding of Myricx Bio, which is now part of Novartis.
The announcement also extended congratulations to the students, postdocs, collaborators, and Myricx colleagues whose efforts were instrumental in this achievement. The World ADC judges were also thanked for their recognition of the work.
